During Wednesday’s Current trade, Shares of Cowen Group Inc (NASDAQ:COWN), lost -1.78% to $4.97.
Cowen Group, Inc. (COWN) declared that George Mihalos has joined Cowen and Company’s Equity Research department as a Director to cover payments and financial information stocks. Mr. Mihalos is based in New York and reports to Robert Fagin, Cowen’s Director of Research.
Mr. Mihalos has nine years of equity research experience in the payments and financial information sector. He joins Cowen from Credit Suisse where he was a research analyst, and formerly held similar roles at Bank of America Merrill Lynch and Bear Stearns.
Mr. Mihalos holds a Bachelor in Business Administration degree from Hofstra University.
Cowen’s technology, media and telecommunications equity research team comprises 13 senior analysts whose coverage spans Computer Services & IT Consulting, Digital Media, Internet, Media, Payments & Financial Information, Semiconductor Capital Equipment, Semiconductors, Software, Telecom & Networking Equipment, and Telecom Services.
Cowen Group, Inc. is a publicly owned asset administration holding company. Through its auxiliaries, the firm provides alternative investment administration, investment banking, research, and sales and trading services for its clients. It manages separate client focused portfolio through its auxiliaries.
Shares of Omnicom Group Inc. (NYSE:OMC), inclined 0.91% to $66.76, during its current trading session.
Zimmerman, Omnicom’s retail growth machine, recently declared the hire of Michael Angelovich as EVP/Director of Planned Planning. In his new role, Angelovich is responsible for planned planning for the agency in addition to leading the Red Light Project, the agency’s heretical retail research engine. Within the role, Michael will also join the expanded leadership team that has revitalized growth for the retail shop.
Michael Goldberg, Chief Executive Officer, had this to say about Angelovich’s arrival: “I was captured by Michael’s ambition, willingness to invent and how much he cared about work. Michael makes insights better, work better and people better – and all that combined makes business better.”
Michael has a stellar track record for building global planned teams and cultivating strong client partnerships, counting progressive industries such as retail, consumer goods and technology. During his tenure with mcgarrybowen, Angelovich assisted the firm win the global Intel business and several key accounts, such as P&G and Staples. Michael also held several senior strategy positions for global agencies counting Publicis, Young & Rubicam and TBWA.
Omnicom Group Inc., together with its auxiliaries, operates as an advertising, marketing, and corporate communications services company in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It offers services in advertising, customer relationship administration, public relations, and specialty communications areas.
RXi Pharmaceuticals Corp (NASDAQ:RXII), during its Wednesday’s current trading session decreased -2.41% to $0.385.
RXi Pharmaceuticals Corp (RXII) declared that it received two Notices of Allowance from the United States Patent and Trademark Office (USPTO). One is on RXi’s novel, self-delivering RNAi platform (sd‑rxRNA®). The patent, titled “Reduced Size Self-Delivering RNAi Compounds,” covers both the composition and methods of use of RXi’s self-delivering platform. The patent, once issued, will be planned to expire in 2031.
In addition, RXi declared that it has also received a Notice of Allowance from the USPTO covering the composition and methods of use for rxRNAori® compounds targeting Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4). These compounds may be beneficial for the treatment of inflammatory diseases and/or metabolic diseases. RXi’s rxRNAori platform are highly potent RNAi compounds which require delivery vehicles to be taken up by cells and tissues of interest. The patent, once issued, will be planned to expire in 2029.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs comprise RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, in addition to for the administration of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma.
Finally, Splunk Inc (NASDAQ:SPLK), gained 2.27%, to $60.65.
Splunk Inc. (SPLK), provider of the leading software platform for real-time Operational Intelligence, recently declared that it will be holding an Investor and Analyst meeting on Tuesday, Sept. 22, 2015. The event will be held in conjunction with .conf2015: The 6th Annual Splunk Worldwide Users’ Conference at the MGM Grand in Las Vegas.
- Godfrey Sullivan, Chairman and CEO, Splunk, will provide a company overview starting at 9 a.m. PDT.
- Dave Conte, chief financial officer, Splunk, will host a financial talk about starting at 11 a.m. PDT.
Splunk, Inc. provides software products that enable organizations to gain real-time operational intelligence in the United States and internationally. The company’s products enable users to collect, index, search, explore, monitor, and analyze data regardless of format or source users. It offers Splunk Enterprise, a machine data engine with collection, indexing, search, reporting analysis, alerting, monitoring, and data administration capabilities; and Splunk Cloud service.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
